APOE and Alzheimer disease: Another possible explanation to this finding could raise from an interaction of the BDNF Val66Met polymorphism with pathological markers of AD, as the APOE-ε4 allele has also been strongly linked to a dose-dependent increase in the prevalence of abnormally elevated cerebral amyloid deposition in CU individuals (Reiman et al. 2009).